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INTRODUCTION
The burden of disease of a specific group of population can
be determined by measuring the difference between actual
health status and ideal health status (1). As for the classical
methods of measuring the actual health status of the popu-
lation of interest, the typical indices are morbidity and mor-
tality. In other words, the two effects of diseases in a certain
population group are divided into the prevalence state and
death. Other measures are related either directly or indirectly
with these two effects, and include pain, suffering, fear, work-
ing hours and income lost, worry, apprehension, and destruc-
tion of the family (2). However, in the case of more advanced
countries, measuring health status only through mortality
is no longer valid, and incidence also has its drawbacks, as it
does not include some measures of improved health status
after suffering from diseases (3). 
Ideal health status values could vary as they depend on value
choices of a certain society. These might include setting lim-
its of ideal life expectancy, granting an age weighting, which
would account for health losses during adolescence, middle
age and senescence, the issue of discounting future health
status with the current level of health, and deciding upon
health loss due to prevalence state and death. As a result, com-
prehensive approaches to actual health status and ideal health
status, which are the two aspects of the burden of disease, are
non-existent due to the lack of an agreed measuring system. 
Recently, a number of approaches for measuring health
status have been developed that combine the mortality and
morbidity levels into a composite indicator. The main rea-
son for producing such as index is that it would provide us
with a measure of the benefits of health intervention. Thus,
health care intervention should be expressed with a single
index uni-dimensional estimation (4). However, as yet these
indices have not been agreed extensively by those responsible
for health care resource allocation (2). 
The allocation of health care resources has recently become
a more important issue in many countries that experienced
resource limitation (5, 6). Thus, the allocation of such lim-
ited available health care resources demands an agreed ratio-
nal allocation principle and the consequent priority setting
is of considerable importance. Ideally, priorities should be
determined on the basis of obtaining the greatest benefit from
health care expenditure (2, 7). However, approaches made
in accord with the rational allocation principle, as related to
deciding benefit from the aspect of health in the public health
fields are nevertheless still not being applied (8). 
In order to rationalize health care allocation, a rational eval-
uation for improving overall health status of the applicable
population must be agreed (9, 10), and to rationally evaluate
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Estimation of the Burden of Major Cancers in Korea
We estimated the burden of diseases in Korea especially caused by major can-
cers using DALY (disability adjusted life year) measurement. Firstly, the burden
of disease due to premature death was estimated by using YLLs (years life lost
due to premature death) measurement developed by the global burden of dis-
ease study group. Secondly, for the calculation of the YLD (years lived with dis-
ability), the following parameters were estimated in the formula; incidence rate,
case fatality rate and disability weight of major cancers. Thirdly, we estimated
DALY of major cancers by adding YLLs and YLDs. The burden of major cancers
for male per 100,000 population was attributed mainly to liver cancer (528.8 per-
son-year), stomach cancer (451.4 person-year), and lung cancer (374.9 person-
year). The burden of major cancers for female per 100,000 population was attribut-
ed mainly to liver cancer (140.0 person-year), stomach cancer (259.7 person-
year), and lung cancer (125.2 person-year). Each of these cancers was respon-
sible for the loss of over 100 person-year per 100,000 population based on our
DALY measurement. We found the DALY method employed was appropriate to
quantify the burden of disease. Thereby, it would provide a rational bases to plan
a national health policy regarding the burden of disease caused by major can-
cers in Korea 
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policies related to improved overall health status, the follow-
ing four informational requirements are prerequisites. The
first requirement is that the information has a reliable epi-
demiological basis and that it accurately evaluates the dis-
ease burden; the second concerns the possible use and distri-
bution status of health care resources; the third involves a
strategic evaluation of health care policy; and the fourth re-
quires information on strategies for improving health and
cost-effectiveness with respect to potentially usable technolo-
gies (11). To enable the possibility of such a rational evalua-
tion, it is essential that we determine what should be mea-
sured and what could be measured. 
Recently, the World Health Organization (WHO), the
World Bank, and the School of Public Health at Harvard
University sanctioned work related to the global burden of
disease (GBD). This research program commenced in 1992
and involved many researchers, and the results have been pub-
lished in many forms (1). Based on the study results of GBD
in each country, these researchers are recommending that in-
dividual nations expedite burden of disease studies at the
national level (national burden of disease: NBD). As a direct
consequence, NBD studies have been or are being performed
in more than 20 countries, including Mexico, Japan, and
several European and African countries (8, 12-15). 
The disease structure in Korea is changing rapidly as in-
comes improve, and the most important characteristics of
the changes in disease structure are caused by the increase in
non-infectious diseases and the importance of chronic diseases
as opposed to acute diseases, and in particular, the mortality
and morbidity status of cancer, is the most representative
example of chronic diseases and which is steadily increasing
(16). In Korea, interest has increased in the cancer field with
the introduction of a comprehensive management plan at the
national level, including the establishment of the National
Cancer Center and the Cancer Research Institute (17, 18). At
this moment in time to arrive at more effective policy mea-
sures and establish strategies to overcome cancer we should
better understand the actual disease burden imposed by can-
cer in Korea and understand the basis of health care resource
allocation. These are the important tasks that can make con-
quering cancer possible. 
As to the above background, this study was carried out to
measure the gaps between ideal health status and present
health status with respect to the burden of disease imposed
by major cancers in Korea.
MATERIALS AND METHODS
To estimate the disease burden of major cancers in Korea,
we followed closely the approach taken in the original GBD
study. First, we estimated the years of life lost due to prema-
ture death (YLLs) from major cancers. Secondly, we estimated
years lived with disability (YLDs) due to cancer. To calculate
YLDs we estimated some of the epidemiological indicators
of major cancers, such as, the incidence rates, fatality rates,
and remission rates. Thirdly, using these results, we calculat-
ed the disability adjusted life years (DALY) of major cancers
in Korea.
The detail of study methods used were as follows. 
To estimate years of life lost due to premature death (YLLs),
we initially developed estimates of population and deaths
by each age group and sex. The estimates of cause-specific
mortality were based on vital registration data, maintained
by the National Statistical Office. These data, available since
1991 in a computerized format, were regarded as being reli-
able, and only 0.8 per cent of causes of death were missing
as of 1995. 
We estimated years of life lost due to premature death
(YLLs) from major cancer diseases. 
Firstly, we estimated the age-specific standard life expectan-
cy, age at death, sex, and cause of death using the national
death certificate data and life table, which is produced by the
National Statistical Office. Estimates of cause-specific mor-
tality were based on vital registration data, maintained by the
National Statistical Office (NSO). Vital event registration,
which contains computerized data from 1991, offers a con-
tinuous means of tracking deaths by age and cause. The data
used for analysis was for the year 1996. 
Secondly, we estimated the age group specific years of life
lost due to premature death using standard expected years of
life lost (SEYLL)
Thirdly, the final burden of disease due to premature death
was estimated by applying the YLLs function as suggested
by the Global Burden of Disease study group.
To estimate years lived with disability (YLDs), the follow-
ing epidemiological parameters were estimated in the for-
mula.
Firstly, the health insurance claim data during the period
1991-1996 were converted to person-based health utiliza-
tion data from claim-based data. Patients who sought health
care for some particular cancer for the first time in 1996 were
considered as incident cases. The estimate of incidence rate
was produced by dividing the number of incident cases by
the population. 
Secondly, case fatality rate was estimated as follows; the
number of deaths due to each type of malignant neoplasm
were divided by the number of incident cases. 
Thirdly, to calculate disability weight, we estimated the
disability weights by the Delphi method. For each cancer
type 20 professional panels were recruited to estimate disabil-
ity weight.
Fourthly, to estimate the expected duration at disability
and the average age at onset, the expected duration of dis-
ability and average age of onset were calculated using the
DISMOD method as developed by the GBD researchers (1). 
We then estimated the final burden of disease due to dis-
ability caused by malignant neoplasms as years lived with606 S.-J. Yoon, H. Lee, Y. Shin, et al.
the disability function, which was supplied by the Global
Burden of Disease study group.
To calculate disability adjusted life years (DALY) for major
cancers in Korea, we used the YLL and YLD results and DALY
of major cancers in Korea were summed.
RESULTS
When the years of life lost due to premature death for male
were calculated using SEYLL based on the 1995 life table
prepared by the National Statistical Office, the results showed
that the lost years due to liver cancers were 128,648 person-
years, stomach cancer 109,517, lung cancer 92,045, esopha-
geal cancer 17,091, pancreatic cancer 17,848, colorectal can-
cer 22,287, non-Hodgkin’s lymphoma 8,806, leukemia 20,
426, bladder cancer 5,366, and prostate cancer 3,486 person-
years. When the burden of disease due to premature death
was calculated per 100,000 men in Korea, the results showed
that the years lost per 100,000 for liver cancer was 578.9 per-
son-years, stomach cancer 492.8, lung cancer 414.2, esopha-
geal cancer 76.9, pancreatic cancer 80.3, colorectal cancer
100.2, non-Hodgkin’s lymphoma 39.6, leukemia 91.9, blad-
der cancer 24.1, and prostate cancer 15.7. Among these can-
cers, those accounting for more than 100 yr per 100,000 men
lost were, liver cancer, stomach cancer, lung cancer, and col-
orectal cancer (Table 1). 
When the years of life lost due to premature death for fe-
males were calculated using SEYLL on the basis of the 1995
life table prepared by NSO, the results showed that 33,766
person-years were lost years due to liver cancers, stomach can-
cer 63,034, lung cancer 30,219, esophageal cancer 1,849,
pancreatic cancer 11,213, colorectal cancer 19,194, non-
Hodgkin’s lymphoma 4,754, leukemia 15,478, cervical can-
cer 11,578, breast cancer 19,328, and ovarian cancer 6,436.
When burden of disease due to premature death was calcu-
lated per 100,000 women in Korea, the results showed that
151.9 person-years were lost per 100,000 women for liver
cancer, stomach cancer 283.7, lung cancer 135.9, esophageal
cancer 8.3, pancreatic cancer 50.1, colorectal cancer 86.4, non-
Hodgkin’s lymphoma 21.4, leukemia 69.7, cervical cancer
52.1, breast cancer 87.0, and ovarian cancer 28.9 person-years.
Among these cancers, those accounting for more than 100
yr per 100,000 women were liver cancer, stomach cancer,
and lung cancer (Table 2). 
When years lived with disability for male were calculated
according to the epidemiological estimate results, the calcu-
lation showed that in the case of Korean men, the YLD were
3252.3 person-years for liver cancer, 3411.7 for stomach can-
cer, 1644.4 for lung cancer, 324.4 for esophageal cancer, 461.4
for pancreatic cancer, 2014.3 for colorectal cancer, 613.3 for
leukemia, 159.9 for non-Hodgkin’s lymphoma, 739.9 for
bladder cancer, and 203.5 for prostate cancer. When these
figures were converted to years per 100,000 in the general
population, years lived with disability per 100,000 were 14.3
person-years for liver cancer, 15.0 for stomach cancer, 7.2 yr
for lung cancer, 8.8 yr for colorectal cancer, 2.0 yr for pancre-
atic cancer, 1.4 for esophageal cancer, 3.2 yr for bladder can-
cer, 0.9 for prostate cancer, 2.7 for leukemia, and 0.7 for non-
Hodgkin’s lymphoma. Liver cancer and stomach cancer show-
≤29 2031.24 2128.07 445.59 68.65 134.23 777.67 1795.12 9413.03 68.89 33.57
30-44 24029.53 14597.38 6509.32 533.58 2205.74 3405.36 1996.29 4634.76 203.10 29.42
45-59 63812.78 36925.38 29831.48 6514.03 7433.52 7543.81 2530.64 3492.86 1168.50 513.61
60-69 26496.05 31694.99 31856.21 6256.73 4964.08 5267.63 1488.91 1883.88 1545.50 1011.28
70≤ 12279.15 24171.24 23402.61 3718.91 3110.50 5292.68 995.06 1002.36 2380.26 1898.26
Total 128648.80 109517.10 92045.20 17091.90 17848.10 22287.10 8806.00 20426.90 5366.30 3486.10
(578.9) (492.8) (414.2) (76.9) (80.3) (100.2) (39.6) (91.9) (24.1) (15.7)
NHL Leukemia
Lung 
cancer
Esophageal 
cancer
Pancreatic 
cancer
Colorectal 
cancer
Bladder 
cancer
Prostate 
cancer
Age group
(yr)
Liver 
cancer
Stomach 
cancer
Table 1. Years of life lost due to premature death by malignant neoplasm for male calculated using SEYLL in Korea
The numbers in parentheses are person-year per 100,000 population. SEYLL, standard expected years of life lost. NHL, Non-Hodgkin's lymphoma.
Unit: person-year
≤29 1014.49 3542.07 651.63 - 74.14 574.74 843.60 6819.34 130.18 1396.01 629.15
30-44 4172.01 12552.13 3413.71 127.50 916.73 3073.08 1187.09 3603.74 3463.50 11355.42 1685.18
45-59 12097.33 15458.26 7635.58 335.52 3112.19 5025.06 1121.77 2561.10 4583.01 10963.83 2213.99
60-69 8559.07 13777.00 7922.97 527.09 3585.73 4634.14 874.82 1420.78 2360.36 2662.04 1007.50
70≤ 7923.70 17705.28 10595.97 859.10 3434.81 5887.14 726.84 1072.82 1041.10 1148.06 900.14
Total 33766.6 63034.7 30219.9 1849.2 11123.6 19194.2 4754.1 15478.8 11578.2 19328.1 6436.0
(151.9) (283.7) (135.9) (8.3) (50.1) (86.4) (21.4) (69.7) (52.1) (87.0) (28.9)
NHL Leukemia
Lung 
cancer
Esophageal 
cancer
Pancreatic 
cancer
Colorectal 
cancer
Breast 
cancer
Cervical 
cancer
Ovarian 
cancer
Age group
(yr)
Liver 
cancer
Stomach 
cancer
Table 2. Years of life lost due to premature death by malignant neoplasm for females calculated using SEYLL in Korea
The numbers in parentheses are person-year per 100,000 population. SEYLL, standard expected years of life lost. NHL, Non-Hodgkin's lymphoma.
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ed more than 10 person-years of disease burden per 100,000
of the population (Table 3).
When years lived with disability for females were calcu-
lated according to the epidemiological estimate results, the
calculations showed that in the case of Korean women, the
YLD were 1119.4 person-years for liver cancer, 1718.6 for
stomach cancer, 774.7 for lung cancer, 80.3 for esophageal
cancer, 341.6 for pancreatic cancer, 1906.9 for colorectal can-
cer, 438.7 for leukemia, 87.7 for non-Hodgkin’s lymphoma,
4,849.5 for cervical cancer, 1865.5 for breast cancer, and 569.3
person years for ovarian cancer. When these figures were con-
verted per 100,000 of the female population, the years lived
with disability per 100,000 were 5.0 person-years for liver
cancer, 7.6 for stomach cancer, 3.4 yr for lung cancer, 8.5 yr
for colorectal cancer, 1.5 yr for pancreatic cancer, 0.4 for eso-
phageal cancer, 21.6 yr for cervical cancer, 8.3 for breast can-
cer, 2.5 for ovarian cancer, 2.0 for leukemia, and 0.4 for non-
Hodgkin’s lymphoma. Cervical cancer accounted for more
than 10 person-years of disease burden per 100,000 of the
female population (Table 4). 
Based on DALY per 100,000 population (the burden of
disease due to premature death is calculated as standard ex-
pected years of life lost (SEYLL)), the priority for burden of
disease due to malignant cancers in Korean men was liver can-
cer (529 person-years), stomach cancer (451 person-years),
lung cancer (374 person-years), colorectal cancer (97 person-
years), leukemia (84 person-years), pancreatic cancer (73 per-
son-years), esophageal cancer (69 person-years), non-Hodg-
kin’s lymphoma (36 person-years), bladder cancer (25 person-
years), and prostate cancer (15 person-years). Among these
≤29 106.5 74.2 129.9 9.1 27.6 119.8 78.6 360.3 43.5 3.9
30-44 776.3 802.3 198.4 39.9 104.9 471.5 38.8 105.1 175.8 15.1
45-59 1603.7 1492.4 553.2 117.6 174.5 846.3 22.7 82.2 304.2 32.3
60-69 554.4 719.6 451.2 108.8 97.7 366.6 13.9 46.3 145.0 45.9
70≤ 211.5 323.2 311.7 49.0 56.7 210.1 5.8 19.3 71.5 106.3
Total 3252.3 3411.7 1644.4 324.4 461.4 2014.3 159.9 613.3 739.9 203.5
(14.3) (15.0) (7.2) (1.4) (2.0) (8.8) (0.7) (2.7) (3.2) (0.9)
NHL Leukemia
Lung 
cancer
Esophageal 
cancer
Pancreatic 
cancer
Colorectal 
cancer
Bladder 
cancer
Prostate 
cancer
Age group
(yr)
Liver 
cancer
Stomach 
cancer
Table 3. Years lived with disability caused by major cancers for males in Korea
The numbers in parentheses are person-year per 100,000 population. NHL, Non-Hodgkin's lymphoma.
Unit: person-year
≤29 51.7 75.5 80.7 34.5 57.4 106.7 220.8 25.3 413.9 79.3 154.6
30-44 235.9 544.8 158.1 9.5 60.3 452.3 101.7 23.4 2832.4 1095.1 214.4
45-59 473.3 605.1 210.3 20.4 98.4 778.1 68.2 28.1 1268.8 604.5 145.4
60-69 232.5 300.0 151.4 10.4 64.8 358.0 31.2 7.2 278.1 73.6 40.8
70≤ 126.0 193.1 174.1 5.5 60.8 211.7 16.7 3.8 56.3 13.1 14.1
Total 1119.4 1718.6 774.7 80.3 341.6 1906.9 438.7 87.7 4849.5 1865.5 569.3
(5.0) (7.6) (3.4) (0.4) (1.5) (8.5) (2.0) (0.4) (21.6) (8.3) (2.5)
NHL Leukemia
Lung 
cancer
Esophageal 
cancer
Pancreatic 
cancer
Colorectal 
cancer
Breast 
cancer
Cervical 
cancer
Ovarian 
cancer
Age group
(yr)
Liver 
cancer
Stomach 
cancer
Table 4. Years lived with disability caused by major cancers for females in Korea
The numbers in parentheses are person-year per 100,000 population. NHL, Non-Hodgkin's lymphoma.
Unit: person-year
Liver cancer 128,649 (514.5) 1 3,252.3 (14.3) 2 131,901.3 (528.8) 1
Stomach cancer 109,517 (436.4) 2 3,411.7 (15.0) 1 112,928.7 (451.4) 2
Lung cancer 92,045 (367.7) 3 1,644.4 (7.2) 4 93,689.4 (374.9) 3
Colorectal cancer 22,287 (88.0) 4 2,014.3 (8.8) 3 24,301.3 (96.8) 4
Leukemia 20,427 (81.7) 5 613.3 (2.7) 6 21,040.3 (84.4) 5
Pancreastic cancer 17,848 (71.3) 6 461.4 (2.0) 7 18,309.4 (73.3) 6
Esophageal cancer 17,092 (67.7) 7 324.4 (1.4) 8 17,416.4 (69.1) 7
NHL 8,806 (35.1) 8 159.9 (0.7) 10 8,965.9 (36.3) 8
Bladder cancer 5,366 (21.3) 9 739.9 (3.2) 5 6,105.9 (24.5) 9
Prostate cancer 3,486 (13.7) 10 203.5 (0.9) 9 3,689.5 (14.6) 10
YLL Ranking YLD Ranking DALY Ranking
Table 5. YLL calculated using SEYLL, YLD, and DALY of major cancers for male in Korea 
The numbers in parentheses are person-year per 100,000 population. YLL, years of life lost; SEYLL, standard expected years of life lost; YLD, years
lived with disability; DALY, disability adjusted life years; NHL, Non-Hodgkin's lymphoma.
Unit: person-year608 S.-J. Yoon, H. Lee, Y. Shin, et al.
cancers, the weight of liver cancer, stomach cancer, and lung
cancer was high, showing a DALY burden of more than 100
person-years per 100,000 of the population (Table 5).
The priority for burden of disease due to malignant cancers
in Korean women was stomach cancer (260 person-years),
liver cancer (140 person-years), lung cancer (125 person-
years), colorectal cancer (95 person-years), cervical cancer (68
person-years), breast cancer (86 person-years), leukemia (64
person-years), pancreatic cancer (46 person-years), non-
Hodgkin’s lymphoma (19 person-years), ovarian cancer (28
person-years), and esophageal cancer (8 person years). Among
these cancers, the weight of liver cancer, stomach cancer, and
lung cancer was particularly high, showing burden of DALY
exceeding 100 person years per 100,000 population (Table 6). 
Fig. 1, 2 show that when the burden of disease due to pre-
mature death was calculated in standard expected years of
life lost (SEYLL), the distribution ratio between the burden
of disease due to premature death, which is one component
of DALY, and the burden of disease due to disability in the
case of men were all under 5% except for bladder cancer
(13%), colorectal cancer (9%), and prostate cancer (5%) (Fig.
1, 2). In the case of women, the distribution ratio of disease
burden due to disability was higher than in men, with a ratio
for stomach cancer of 2.9%, liver cancer 3.5%, lung cancer
2.7%, colorectal cancer 8.9%, cervical cancer 31%, breast
cancer 9%, leukemia 3.1%, pancreatic cancer 3.2%, non-
Hodgkin’s lymphoma 2%, ovarian cancer 8.8%, and eso-
phageal cancer 5.1%. These figures indicate that the burden
of disease due to premature death caused by cervical and breast
cancer is relatively higher than the burden of disease due to
disability compared to other diseases. 
DISCUSSION
After being first introduced by the World Bank report
sponsored by the World Health Organization and the World
Bank in 1993, disability adjusted life year (DALY), a single
Stomach cancer 63,035 (252.1) 1 1,718.6 (7.6) 4 64,753.6 (259.7) 1
Liver cancer 33,767 (135.1) 2 1,119.4 (5.0) 5 34,886.4 (140.0) 2
Lung cancer 30,220 (121.8) 3 774.7 (3.4) 6 30,994.7 (125.2) 3
Colorectal cancer 19,194.2 (86.4) 4 1,906.9 (8.5) 2 21,101.1 (94.9) 4
Cervical cancer 11,572 (46.3) 7 4,849.5 (21.6) 1 16,421.5 (68.0) 6
Breast cancer 19,328 (77.3) 5 1,865.5 (8.3) 3 21,193.5 (85.6) 5
Leukemia 15,478 (61.9) 6 438.7 (2.0) 8 15,916.7 (63.9) 7
Pancreatic cancer 11,123.6 (44.4) 8 341.6 (1.5) 9 11,465.2 (45.9) 8
NHL 4,754.1 (19.0) 10 87.7 (0.4) 10 4,841.8 (19.4) 10
Ovarian cancer 6,436.0 (25.7) 9 569.3 (2.5) 7 7,005.3 (28.2) 9
Esophageal cancer 1,849.2 (7.3) 11 80.3 (0.4) 11 1,929.5 (7.7) 11
YLL Ranking YLD Ranking DALY Ranking
Table 6. YLL calculated using SEYLL, YLD, and DALY of major cancers for female in Korea 
The numbers in parentheses are person-year per 100,000 population.  YLL, years of life lost; SEYLL, standard expected years of life lost; YLD, years
lived with disability; DALY, disability adjusted life years; NHL, Non-Hodgkins lymphoma.
Unit: person-year
Prostate ca
Bladder ca
NHL
Esophageal ca
Pancres ca
Leukemia
Colorectal ca
Lung ca
Stomach ca
Liver ca
0 100 200 300 400 500 600
Fig. 1. The proportion of YLD in DALY of major cancers for male
in Korea. YLL, years of life lost; YLD, years lived with disability;
DALY, disability adjusted life years; NHL, Non-Hodgkins lymphoma.
Esophagus ca
Ovarian ca
NHL
Pancres ca
Leukemia
Breast ca
Cervix ca
Colorectal ca
Lung ca
Liver ca
Stomach ca
0 50 100 150 200 250 300
Fig. 2. The proportion of YLD in DALY of major cancers for
female in Korea. YLL, years of life lost; YLD, years lived with dis-
ability; DALY, disability adjusted life years; NHL, Non-Hodgkins
lymphoma.
YLL
YLD
YLL
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indicator that comprehensively evaluates health status from
the point of view of premature death and disability, is hav-
ing a considerable influence on the establishment of a pub-
lic health policy primarily in the developing world (19). 
The DALY indicator as applied in the present study is a
single measure of the summation of lost time due to prema-
ture death and time lived with disability. The main reason
why this indicator causes so much interest in the related fields
of study is the fact that this indicator may be used as a mea-
suring tool that can explain the level of death and the degree
of prevalence simultaneously (19). 
As for the problems related to the data used in the present
study, first, the fact that the medical electronic data used for
the study that were utilized to estimate the incidence and the
number of affected patients disagree with the actual named
diagnoses is of real concern names plays an impairing factor.
Compared to the results of previous studies on estimated
incidence (20, 21), the estimated incidences used in the pre-
sent study showed similar rates in terms of major types of
cancer. However, there is a possibility that the incidences
could have been overestimated according to the medical data
utilized. This is because there is currently a tendency to docu-
ment cases at a more severe level because of the need to claim
medical insurance.
The second problem is the inaccurate electronic statistical
data on the cause of death. In the case of electronic statistical
data used to estimate the mortality for each disease, a doctor
diagnoses the final cause of death and those cases with a sub-
mitted death certificate is low at about 50-60% (16). More-
over, the statistics are difficult to verify in retrospect, never-
theless, we believe that the possibility is high that the stated
cause of death is probably at odds the actual cause of death,
and it is likely that the estimation of mortality in the present
study includes a significant bias. 
The analysis results between the burden of major cancers
and the ranking of causes of death showed that there was
almost no difference in the order of priority. The reason for
this lack of difference is interpreted as being due to the char-
acteristics of malignant cancers. In other words, malignant
cancers do not have unique treatment drugs and do not have
high remission rates so that when early death is prevalent,
the burden of disease according to the years of life lost due to
early death takes on a relatively high weighting compared
to the burden of disease due to disability. In this case, DALY
in the majority, would be effected by a loss of disease burden,
i.e., and the results of the present study could be similarly
affected. However, the following difference exists in the set-
ting of disease priorities according to each of the existing
levels and prevalences of death. 
We were able to quantitatively determine the causes and
the patterns of the main burden of disease according to the
distribution ratio of the burden of disease, that is, the con-
tribution due to early death on one hand and disability on
the other, which are the components of DALY. The results
showed that the distribution ratios of malignant cancers,
other than bladder cancer (13%), colorectal cancer (9%),
and prostate cancer (5%), in Korean men are less than 5%.
In the case of bladder cancer, colorectal cancer, and prostate
cancer, the results were believed to have been caused by their
lower mortalities compared to other cancers. 
In the case of Korean women, the distribution ratio of bur-
den of disease due to disability was shown to be higher than
in men. This was particularly true of cervical cancer, which
showed a ratio of 31% and breast cancer 9%, indicating the
burden of disease due to early death is relatively high com-
pared to the burden of disease due to disability compared to
other cancers. This result might be interpreted to be due to
the severity of the cancers themselves, requiring lower mor-
tality rates and the activation of early detection programs. 
The results of the present study could be used in the fol-
lowing manner. 
First, they could be used as basic data to determine the pri-
ority of public health policies. In other words, they could
provide specific quantitative data, which would allow more
effective use of limited resources (22). 
Secondly, the results could be used to determine the prior-
ities of studies in Korea related to cancers. Thus, when bud-
gets and manpower related to this type of study are limited,
the results could be used as an index to determining the larg-
er themes of disease burden and allow a more quantitative
approach to decision making. 
Thirdly, by comparing the results of the present study with
burden of disease with other studies conducted abroad, DALY
could provide information that would allow comparisons of
health status and disease burden. 
In order to activate studies on disease burden utilizing
DALY, which was the health status measurement indicator
applied in this study, and raise the possibility of applying
these results, the development of the resource data for accu-
rately estimating the related epidemiological indicators is
urgently required. In other words, we need not only to im-
prove the accuracy and completeness of the cause of death
data of and medical claim data, which were utilized by the
present study, but also to have require a monitoring system
to enable us to estimate the related epidemiological indica-
tors (mortality and incidences). With the precondition of
improving these factors, studies need to be broadened into
the area of disease burden evaluation not only of the chronic
diseases, such as cancers examined in the present study, but
also of the risk factors that are considered to be important
health issues, which heavily affect the health of the Korean
people, such as smoking and drinking. In addition, an eval-
uation of the disease burden of the 10 major causes of death
in Korea, and comparing these with the leading causes of
death in advanced countries would allow us to assess the pos-
sibility of applying such differences as a comparative index. 
We measured disability adjusted life years (DALY) and
the priority of disease burden for the major types of cancer,610 S.-J. Yoon, H. Lee, Y. Shin, et al.
which is the major cause of death in Korea. This study was
undertaken to assess the possibility of applying the results
from the basis of improved priority assessment. 
Despite the limitations of the data used in the present
study, these results present a very important message, as
they are helpful for determining the priority of the future
policies in public health, that is, they offer more specific
quantitative data that can be used for more effective utiliza-
tion of our limited resources.
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